Kushal Naha, MD

This article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.

Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.